Frazier Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Frazier Management’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,827,415	Closed	-$115M	–	21
2021 Q4	$115M	Hold	5,827,415	–	–	8.82%	2
2021 Q3	$187M	Hold	5,827,415	–	–	14.97%	2
2021 Q2	$197M	Hold	5,827,415	–	–	18.19%	2
2021 Q1	$219M	Hold	5,827,415	–	–	17.56%	2
2020 Q4	$194M	Hold	5,827,415	–	–	14.91%	2
2020 Q3	$214M	Hold	5,827,415	–	–	19.18%	2
2020 Q2	$192M	Sell	5,827,415 -1,456,854	-20%	-$56M	16.84%	2
2020 Q1	$188M	Hold	7,284,269	–	–	21.33%	2
2019 Q4	$227M	Buy	+7,284,269	New	+$183M	38.04%	1

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Frazier Management's PHAT Position: Q1 2022 in Review

Frazier Management sold out of Phathom Pharmaceuticals (PHAT) in Q1 2022, closing a stake of 5,827,415 shares — an estimated $115M sold.

Frazier Management first reported a position in PHAT in Q4 2019 and held it in 9 quarters. The position peaked at $227M in Q4 2019. 82 funds tracked by Wall St. Rank hold PHAT as of Q1 2022.

Frazier Management reported no remaining Phathom Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Frazier Management sold 5,827,415 Phathom Pharmaceuticals shares in Q1 2022, an estimated $115M.
Frazier Management first reported a position in Phathom Pharmaceuticals in Q4 2019 and held it in 9 quarters.
Frazier Management's Phathom Pharmaceuticals position peaked at $227M in Q4 2019.
82 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.